Only 9.8% of NSCLC patients without TTF-1 expression harbored EGFR mutations, and the lack of TTF-1 expression had a high NPV (90.2%) for EGFR gene mutation. This evidence concerns the gene RHOH and non-small cell lung carcinoma.